Clearbridge Investments LLC Has $387.34 Million Stock Position in argenx SE (NASDAQ:ARGX)

Clearbridge Investments LLC grew its holdings in argenx SE (NASDAQ:ARGX) by 6.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 629,828 shares of the company’s stock after acquiring an additional 40,330 shares during the quarter. Clearbridge Investments LLC’s holdings in argenx were worth $387,344,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Whipplewood Advisors LLC bought a new position in shares of argenx in the 4th quarter valued at about $37,000. Global Retirement Partners LLC grew its stake in argenx by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after purchasing an additional 48 shares in the last quarter. Jones Financial Companies Lllp increased its position in shares of argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock worth $41,000 after purchasing an additional 61 shares during the last quarter. Whittier Trust Co. of Nevada Inc. raised its stake in shares of argenx by 78.6% during the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company’s stock worth $46,000 after purchasing an additional 33 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its holdings in shares of argenx by 38.2% in the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock valued at $47,000 after buying an additional 21 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

argenx Stock Down 0.7 %

ARGX stock opened at $589.15 on Friday. The company’s 50-day moving average price is $628.26 and its two-hundred day moving average price is $601.66. argenx SE has a 12 month low of $352.77 and a 12 month high of $678.21. The firm has a market cap of $35.80 billion, a P/E ratio of -669.49 and a beta of 0.59.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $761.22 million during the quarter, compared to analysts’ expectations of $678.52 million. Equities analysts predict that argenx SE will post 3.13 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on ARGX. Robert W. Baird increased their price target on shares of argenx from $650.00 to $680.00 and gave the company a “neutral” rating in a research note on Tuesday, March 4th. JMP Securities lifted their price target on argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a report on Tuesday, January 14th. Truist Financial restated a “buy” rating and issued a $700.00 price objective (up previously from $660.00) on shares of argenx in a research note on Tuesday, January 14th. Guggenheim boosted their target price on argenx from $775.00 to $1,100.00 and gave the stock a “buy” rating in a report on Monday, March 10th. Finally, Citigroup reaffirmed an “outperform” rating on shares of argenx in a research report on Friday, February 28th. Three research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, argenx has an average rating of “Moderate Buy” and a consensus price target of $687.00.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.